Neil F. McFarlane
CIK: 0001681098
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ZEVRA THERAPEUTICS, INC.
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Oct 12, 2026ZVRA
ZEVRA THERAPEUTICS, INC.
Sale(S)Direct20K shares at avg. $11.25$225K - Oct 10, 2026ZVRA
ZEVRA THERAPEUTICS, INC.
Exercise(M)Direct50K shares- - Feb 9, 2026ZVRA
ZEVRA THERAPEUTICS, INC.
Sale(S)Direct14.6K shares at avg. $8.56$125K - Feb 7, 2026ZVRA
ZEVRA THERAPEUTICS, INC.
Exercise(M)Direct37.5K shares- - Feb 2, 2026ZVRA
ZEVRA THERAPEUTICS, INC.
Sale(S)Direct91K shares at avg. $9.38$853K - Jan 31, 2026ZVRA
ZEVRA THERAPEUTICS, INC.
Exercise(M)Direct233.3K shares- - Jan 29, 2026ZVRA
ZEVRA THERAPEUTICS, INC.
Award(A)DirectStock Option (right to buy)
250K shares- - Jan 29, 2026ZVRA
ZEVRA THERAPEUTICS, INC.
Award(A)DirectRestricted Stock Unit
125K shares- - Oct 10, 2025ZVRA
ZEVRA THERAPEUTICS, INC.
Exercise(M)Direct50K shares- - Oct 10, 2025ZVRA
ZEVRA THERAPEUTICS, INC.
Sale(S)Direct19.5K shares at avg. $10.82$211K - Feb 14, 2025ZVRA
ZEVRA THERAPEUTICS, INC.
Sale(S)Direct30.5K shares at avg. $8.05$246K - Feb 13, 2025ZVRA
ZEVRA THERAPEUTICS, INC.
Sale(S)Direct61.3K shares at avg. $7.86$481K - Feb 7, 2025ZVRA
ZEVRA THERAPEUTICS, INC.
Award(A)DirectStock Option (right to buy)
225K shares- - Feb 7, 2025ZVRA
ZEVRA THERAPEUTICS, INC.
Award(A)DirectRestricted Stock Unit
112.5K shares- - Jan 31, 2025ZVRA
ZEVRA THERAPEUTICS, INC.
Exercise(M)Direct233.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 12, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | Sale(S) | 20,000 | $11.25 | $224,948 | Direct |
| Oct 10, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | Exercise(M) | 50,000 | - | $0 | Direct |
| Feb 9, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | Sale(S) | 14,625 | $8.56 | $125,186 | Direct |
| Feb 7, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | Exercise(M) | 37,500 | - | $0 | Direct |
| Feb 2, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | Sale(S) | 91,000 | $9.38 | $853,425 | Direct |
| Jan 31, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | Exercise(M) | 233,334 | - | $0 | Direct |
| Jan 29, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | Award(A) Stock Option (right to buy) | 250,000 | - | - | Direct |
| Jan 29, 2026 | ZVRA ZEVRA THERAPEUTICS, INC. | Award(A) Restricted Stock Unit | 125,000 | - | - | Direct |
| Oct 10, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | Exercise(M) | 50,000 | - | - | Direct |
| Oct 10, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | Sale(S) | 19,500 | $10.82 | $210,908 | Direct |
| Feb 14, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | Sale(S) | 30,544 | $8.05 | $245,962 | Direct |
| Feb 13, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | Sale(S) | 61,273 | $7.86 | $481,428 | Direct |
| Feb 7, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | Award(A) Stock Option (right to buy) | 225,000 | - | - | Direct |
| Feb 7, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | Award(A) Restricted Stock Unit | 112,500 | - | - | Direct |
| Jan 31, 2025 | ZVRA ZEVRA THERAPEUTICS, INC. | Exercise(M) | 233,333 | - | - | Direct |
1-15 of 15 transactions
About McFarlane Neil F.
McFarlane Neil F. (SEC CIK 0001681098) files insider reports with the SEC as President and CEO of ZEVRA THERAPEUTICS, INC. (ZVRA).
Signal8 holds 7 ownership filings by McFarlane Neil F., all Form 4s, filed between Feb 3, 2025 and Oct 13, 2026. Those filings report 15 transactions, from Jan 31, 2025 to Oct 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on McFarlane Neil F.'s filings is in BOSTON, MA.
Recent filings by McFarlane Neil F.
- Oct 12, 2026: Open-market sale of ZVRA shares (Form 4, code S).
- Oct 10, 2026: Option exercise of ZVRA shares (Form 4, code M).
- Feb 9, 2026: Open-market sale of ZVRA shares (Form 4, code S).
- Feb 7, 2026: Option exercise of ZVRA shares (Form 4, code M).
- Feb 2, 2026: Open-market sale of ZVRA shares (Form 4, code S).
Other insiders filing for ZEVRA THERAPEUTICS, INC. (ZVRA)
- Thompson Rahsaan, Chief Legal & Compliance
- Watton Corey Michael, Director
- FAVORITO TAMARA A, Director
- Secor Alicia, Director
- Calder Douglas W, Director
- Anderson Thomas, Director